BRAF and non-small cell lung carcinoma: In a phase II trial enrolling patients (N = 57) with metastatic BRAF V600E–mutant NSCLC previously treated with chemotherapy, combination of dabrafenib 150 mg twice daily plus trametinib 2 mg once daily in continuous 21-day cycles provided an objective response rate (ORR) of 63.2%, including 2 (3.5%) patients with complete response (CR) and 34 (59.6%) with partial response (PR).